僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Refanezumab （GSK249320） is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein （MAG）. Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier （BBB） in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke